Kamada Ltd. (NASDAQ:KMDA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.
According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “
Other analysts have also issued research reports about the stock. Jefferies Group LLC reissued a “buy” rating and issued a $7.00 price target (down previously from $9.00) on shares of Kamada in a research report on Wednesday, August 2nd. TheStreet lowered shares of Kamada from a “c-” rating to a “d+” rating in a research report on Tuesday, August 1st. Finally, ValuEngine lowered shares of Kamada from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating and two have given a buy rating to the stock. Kamada presently has an average rating of “Hold” and a consensus price target of $8.50.
Shares of Kamada (KMDA) remained flat at $4.75 on Wednesday. The company had a trading volume of 20,711 shares. The firm’s market capitalization is $177.65 million. Kamada has a one year low of $3.75 and a one year high of $8.61. The stock has a 50 day moving average price of $4.57 and a 200 day moving average price of $6.03.
Kamada (NASDAQ:KMDA) last posted its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.01. Kamada had a negative net margin of 2.24% and a negative return on equity of 2.94%. The company had revenue of $32.55 million for the quarter, compared to analyst estimates of $33.30 million. During the same quarter in the previous year, the firm posted ($0.04) earnings per share. The company’s quarterly revenue was up 70.7% compared to the same quarter last year. Equities research analysts predict that Kamada will post $0.09 earnings per share for the current fiscal year.
WARNING: This piece of content was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/05/zacks-investment-research-downgrades-kamada-ltd-kmda-to-sell.html.
A number of institutional investors have recently bought and sold shares of the stock. Paulson & CO. Inc. increased its holdings in Kamada by 8.2% during the 2nd quarter. Paulson & CO. Inc. now owns 790,800 shares of the biotechnology company’s stock worth $4,745,000 after acquiring an additional 60,000 shares during the period. Navellier & Associates Inc bought a new stake in Kamada during the 2nd quarter worth approximately $303,000. Nexthera Capital LP bought a new stake in Kamada during the 2nd quarter worth approximately $1,805,000. Vanguard Group Inc. increased its holdings in Kamada by 6.5% during the 2nd quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock worth $2,810,000 after acquiring an additional 28,382 shares during the period. Finally, Edmond DE Rothschild Holding S.A. increased its holdings in Kamada by 10.5% during the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 42,200 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 4,000 shares during the period. 7.29% of the stock is currently owned by institutional investors and hedge funds.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.